Value through Innovation03 September 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

22.06.2013

Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with Type 2 Diabetes

- For Non-US and Non-UK Media
17.06.2013

New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF

- For media outside of the US, the UK & Canada only
13.06.2013

Boehringer Ingelheim’s investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients

- For media outside USA, UK and Canada only
11.06.2013

Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association® Scientific Sessions

- Ex US & UK Medical Media Only
08.06.2013

Boehringer Ingelheim’s investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia

- For media outside USA, UK and Canada only
06.06.2013

Boehringer Ingelheim pioneers biopharmaceuticals move to China

03.06.2013

LUME-Lung 1: Nintedanib* plus chemotherapy extends the life of lung cancer patients with adenocarcinoma

- For non U.S. Media Only
01.06.2013

Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study

- For non U.S. Media Only
28.05.2013

New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation

- Not intended for media in the UK, the US or Canada
24.05.2013

Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"

- For Non-U.S. and Non-UK media
22.05.2013

Boehringer Ingelheim responds to FDA warning letter

22.05.2013

Wireless Pill Bottle Wins Healthcare Innovation World Cup

21.05.2013

Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response

- For Media outside the U.S., Canada and UK
17.05.2013

Change in the Board of Managing Directors at Boehringer Ingelheim

16.05.2013

ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment

16.05.2013

ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC

- For non U.S. Media Only
06.05.2013

Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases

25.04.2013

Boehringer Ingelheim Announces a Strong 2012 Performance in China